NASDAQ:OTLK
Outlook Therapeutics Inc. Stock News
$9.37
+0.690 (+7.95%)
At Close: Mar 27, 2024
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy
01:01pm, Thursday, 21'st Mar 2024
Oncobiologics (OTLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
7 of the Best Speculative Stocks You Can Snag for Less Than $1
03:36pm, Wednesday, 06'th Mar 2024
I'm about to drop a truth bomb about speculative stocks under $1. Back when I was a freshman in college, the on-campus security officer had this to say: “Tijuana?
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
01:37pm, Sunday, 25'th Feb 2024
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
09:11am, Wednesday, 24'th Jan 2024
Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.
Best Penny Stocks To Buy Today? 3 To Watch This Week
12:17pm, Monday, 27'th Nov 2023
Penny stocks, or “stocks under $5,” tend to occupy volatile territory with occasional meteoric runs. While savvy short-term traders eagerly scan for these explosive upside trades, penny stocks rem
Invest In Penny Stocks? Is It Worth It & 4 To Watch Now
02:12pm, Tuesday, 07'th Nov 2023
If you're looking for penny stocks to invest in right now, you've got your work cut out for you. That's because the initial strategy when approaching cheap stocks is to trade them in the short term in
3 Penny Stocks To Buy According To Analysts, Targets Up To 365%
05:09pm, Friday, 03'rd Nov 2023
Penny stocks, defined as stocks trading under $5 per share, present traders and investors with opportunities for explosive returns. However, the penny stock territory also comes loaded with substantia
5 Most Active Penny Stocks Today & Why They're Moving Now
02:11pm, Wednesday, 01'st Nov 2023
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.
Outlook Therapeutics® to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference
08:05am, Wednesday, 01'st Nov 2023
Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET
Best Penny Stocks Under $1? 4 To Watch This Week
10:32am, Thursday, 19'th Oct 2023
What are the best penny stocks under $1? If you saw this headline, that's probably a question you have heading into the second half of the week.
4 Top Penny Stocks To Buy For Under $5
03:33pm, Wednesday, 18'th Oct 2023
Looking at the stock market today is like watching an action movie. One minute the bulls are stampeding and stocks are rising.
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
08:05am, Thursday, 21'st Sep 2023
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET
Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08:05am, Tuesday, 05'th Sep 2023
Live video webcast presentation on Wednesday, September 13th at 9:30 AM ET Live video webcast presentation on Wednesday, September 13th at 9:30 AM ET
Why Is Outlook Therapeutics (OTLK) Stock Down 78% Today?
08:16am, Wednesday, 30'th Aug 2023
Outlook Therapeutics (NASDAQ: OTLK ) stock is taking a beating on Wednesday after getting a rejection letter from the FDA. That letter has to do with its biologics license application (BLA) for ONS-5
Outlook Therapeutics collapses as FDA rejects application for eye drug
07:16am, Wednesday, 30'th Aug 2023
Outlook Therapeutics Inc (NASDAQ:OTLK) stock collapsed, losing some 70% of its value in premarket, after the drug discovery firm's potential treatment for eye disease was rejected by the US Food and D